|
2025
|
G/S
|
Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for ... |
|
|
G/S
|
Pharmaceutical services, namely, processing online and telephone prescription orders in retail an... |
|
|
G/S
|
Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on... |
|
|
G/S
|
Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for use in der... |
|
|
Invention
|
Methods of treating multiple sclerosis.
The disclosure relates to methods of treating multiple s... |
|
|
Invention
|
Dosing regimen for a selective s1p1 receptor agonist.
The invention relates to pharmaceutical co... |
|
|
Invention
|
Method of treatment with tradipitant.
This application relates to a method of treatment with tra... |
|
|
Invention
|
Treatment of dry eye disease. The disclosure provides methods of treating dry eye disease in a hu... |
|
|
Invention
|
Method of treatment with tradipitant.
Disclosed herein is a method of treatment of an individual... |
|
|
Invention
|
Method and compositions for the treatment of onychomycosis. The invention relates generally to th... |
|
|
Invention
|
Treatment of circadian rhythm disorders.
Embodiments of the invention relate to the use of a mel... |
|
|
Invention
|
Highly purified pharmaceutical grade tasimelteon.
A process for preparing a batch of highly puri... |
|
2024
|
Invention
|
Method of treatment with milsaperidone.
Described herein is an improved method of treatment with... |
|
|
Invention
|
Liquid tasimelteon formulations and methods of use thereof. Liquid suspensions of tasimelteon and... |
|
|
Invention
|
Method of treatment with tradipitant.
Methods of treating an individual experiencing or at risk ... |
|
|
Invention
|
Multiple myeloma treatment.
The invention relates generally to the treatment of multiple myeloma... |
|
|
Invention
|
Method of treatment.
One embodiment of the invention provides a method for administering tasimel... |
|
|
Invention
|
Highly purified pharmaceutical grade tasimelteon. A process for preparing a batch of highly purif... |
|
|
Invention
|
Tasimelteon for use in the treatment of delayed sleep-wake phase disorder. The invention relates ... |
|
|
Invention
|
Melatonin agonist treatment.
Melatonin Agonist, MA-1, is administered at effective doses. |
|
|
Invention
|
Method of treatment with iloperidone. Described herein is an improved method of treatment with il... |
|
|
Invention
|
Method of treatment.
Embodiments of the invention relate generally to the treatment of schizophr... |
|
|
Invention
|
Method of treatment.
Embodiments of the invention relate to the treatment of sleep disturbances ... |
|
|
Invention
|
Tasimelteon for use in the treatment of patients with optic nerve hypoplasia in order to improve ... |
|
|
Invention
|
Antisense oligonucleotide (aso) gene inhibition and treatment. Embodiments of the invention relat... |
|
|
Invention
|
Use of tradipitant in motion sickness.
Disclosed herein is a method of treating or preventing mo... |
|
|
Invention
|
Depot administration of iloperidone.
Methods of preparing and administering an injectable depot ... |
|
|
Invention
|
Sleep or post-sleep performance.
The invention relates generally to improving sleep, post-sleep ... |
|
|
Invention
|
Treatment of disorders with tasimelteon.
Tasimelteon improves sleep in individuals experiencing ... |
|
|
Invention
|
Tasimelteon for treating circadian rhythm sleep disorder. The invention provides methods of impro... |
|
|
Invention
|
Methods of treating multiple sclerosis. The disclosure relates to methods of treating multiple sc... |
|
|
G/S
|
Insurance services, namely, insurance eligibility review and verification and consultation in the... |
|
|
Invention
|
Improved use of tradipitant in motion sickness.
Disclosed herein is an improved method of treati... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharm... |
|
|
Invention
|
Treatment of circadian rhythm disorders. Embodiments of the invention relate to the use of a mela... |
|
|
G/S
|
Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical p... |
|
2023
|
Invention
|
Methods of treatment with tradipitant. Disclosed herein are methods of administration of tradipit... |
|
|
Invention
|
Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia. Embodiments of th... |
|
|
Invention
|
Treatment of acute anxiety with an alpha-7 nicotinic acetylcholine receptor modulator.
Disclosed... |
|
|
Invention
|
Iloperidone metabolite for use in the treatment of psychiatric disorders.
R-P88 is used for the ... |
|
|
G/S
|
Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and... |
|
|
Invention
|
Method of treatment with tradipitant.
Disclosed herein is a method of treatment of gastric motil... |
|
|
Invention
|
Pharmaceutical combination comprising ponesimod.
The present invention relates to a pharmaceutic... |
|
|
Invention
|
1 receptor agonist. The present invention relates to a pharmaceutical combination comprising a fi... |
|
|
Invention
|
Treatment of parkinson's disease and parkinson's disease psychosis.
The invention relates genera... |
|
|
Invention
|
Trichostatin a (tsa) sensitivity in the treatment of tumors.
Embodiments of the invention relate... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations fo... |
|
|
Invention
|
Methods of slowing an increase in brain ventricular volume.
The disclosure relates to methods of... |
|
2022
|
Invention
|
Prediction of severity of covid-19 and methods of treatment.
The invention relates generally to ... |
|
|
Invention
|
Methods for treating multiple sclerosis.
The disclosure relates to methods of preserving myelina... |
|
|
Invention
|
Treatment of lower respiratory tract infection with tradipitant.
Disclosed herein is a method of... |
|
|
Invention
|
Treatment or prevention of sars-cov-2 infection using (s)-crizotinib.
Embodiments of the inventi... |
|
|
Invention
|
Antisense oligonucleotide (aso) gene inhibition and treatment.
Embodiments of the invention rela... |
|
|
G/S
|
Pharmaceutical preparations containing tasimelteon for use in the treatment of Autism Spectrum Di... |
|
|
G/S
|
Pharmaceutical and medicinal preparations for the treatment, prevention, or amelioration of sympt... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of multiple sclerosis Providing information related... |
|
|
G/S
|
Providing information related to multiple sclerosis and treatments therefor |
|
2021
|
Invention
|
Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist.
D... |
|
|
G/S
|
Providing information in the field of multiple sclerosis |
|
|
G/S
|
Pharmaceutical preparations for the treatment of multiple sclerosis |
|
2020
|
G/S
|
Providing information in the field of treatment and management of multiple sclerosis |
|
|
G/S
|
Pharmaceutical preparations, in liquid form and containing tasimelteon, for use in the treatment ... |
|
|
G/S
|
Pharmaceutical preparations, containing tasimelteon, for use in the treatment of Smith-Magenis Sy... |
|
2019
|
G/S
|
Pharmaceutical preparations for the treatment of multiple sclerosis |
|
|
G/S
|
Pharmaceutical preparations, containing tasimelteon, for use in the treatment of circadian rhythm... |
|
2016
|
G/S
|
Pharmaceutical preparations and substances for use in the
treatment of the central nervous syste... |
|
|
G/S
|
Pharmaceutical preparations and substances for use in the treatment of schizophrenia; pharmaceuti... |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical preparations and substances for use in the treatment ... |
|
|
G/S
|
Business administration connected with the provision of patient access to pharmaceuticals; busine... |
|
2015
|
G/S
|
pharmaceutical preparations and substances for use in the treatment of the central nervous system... |
|
2014
|
G/S
|
Pharmaceutical preparations for use in the treatment of
diseases and disorders of the central ne... |
|
|
G/S
|
Pharmaceutical preparations for use in the treatment of diseases and disorders of the central ner... |
